Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India 80 Percent Through Testing Drug Samples For Counterfeits

This article was originally published in PharmAsia News

Executive Summary

India's Drug Controller General says the agency has collected 31,500 samples of drugs in its quest to determine which may be evading price regulations. The director of the agency said DCGI intends to enforce a new law that imposes stringent penalties on changes in drug compositions without its approval. Dr. Surinder Singh said some companies are evading price controls by retaining the brand name of the drugs after removing the active pharmaceutical ingredient subject to controls. State drug inspectors who collected the samples have examined about 80 percent of them in detail to determine which may be in violation. A report is expected to be issued in December. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts